Testing an experimental pill for IgA nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an experimental pill (NTQ5082) for people with IgA nephropathy, a kidney disease that can cause protein in the urine and kidney damage. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and weigh at least 88 pounds (40 kg).
- Your doctor must have confirmed IgA nephropathy with a kidney biopsy within the last 8 years.
- You need to have high protein in your urine (a sign the disease is active) and your kidney function must be above a certain level.
- You must have received vaccines against meningitis and pneumonia.
- You must be taking a stable dose of blood pressure medication (RAS inhibitor) for at least 3 months.
- You cannot be pregnant or planning pregnancy, and you must agree to use contraception during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This trial tests a new drug, SHR-2173, for people with IgA nephropathy who still have a lot of protein in their urine despite standard care. The goal is to see if it can help protect kidney function.
This trial tests a new medicine called NM8074 for people with IgA nephropathy (a kidney disease). The medicine is given as an infusion and aims to slow down the damage to your kidneys. If you have this condition and meet the health requirements, the trial might help you manage your kidney health.
This study tests a new drug, MY008211A, for people with a type of kidney disease called IgA nephropathy. The goal is to see if it can reduce protein in the urine and help protect kidney function. You must have had a kidney biopsy confirming the diagnosis and be on stable standard care.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
Hear when a new Primary IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.